Your links have seen brilliant. I have been doing a bit more reading on our investment; more particularly the study into the safety of the mesenchymal stromal cell (coined safe cell) courtesy of the Review by Lalu et al 2012.
Basically the study has reviewed all peer reviewed data on MSC's from what I believe are 3 largest medical databases; Medline, Embase and the Cochrane central register for controlled trials.
Now what they found was that there were 36 clinical trials ranging from 1980 onwards - The data set is about 1100 patients think total.
At the conclusion of the paper it states "Conclusions
Our study provides a systematic examination for adverse events related to the use of MSCs. We did not identify any significant safety signals other than transient fever. Results from our systematic review should provide some assurance to investigators and health regulators that, with the present evidence, this innovative therapy appears safe."
"Based on the current clinical trials, MSC therapy appears safe. However, further larger scale controlled clinical trials with rigorous reporting of adverse events are required to further define the safety profile of MSCs."
If I research this correctly Cynata's Cymerus technology acquired the cell from the MAB not the mesenchymal stromal cell. Cynata suggests this patented technology coupled with induced IPS results in many benefits as per the presentation. I am very excited because the pre cursor of MSC's are MAB's - less complex.
Allen Bollands has backlisted Cynata for this reason. By the looks of this Trials may go very well.
Get set.
ECQ Price at posting:
2.8¢ Sentiment: Buy Disclosure: Held
